• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌治疗中的治疗策略(作者译)

[Therapeutic strategies in the treatment of breast cancer (author's transl)].

作者信息

Huber H, Gattringer C, Grünewald K, Margreiter R, Mikuz G, Frommhold H, Senn H J, Braunsteiner H

出版信息

Wien Klin Wochenschr. 1981 Sep 18;93(17):531-41.

PMID:7303699
Abstract

Breast cancer is the most common cause of cancer death in women. The probability of being cured of this disease is below 50%. However, for certain stages of disease prognosis can be improved by the application of modern therapeutic strategies. The present paper deals firstly with the relationship between prognosis, staging, and tumour cell characteristics (receptor status and cell kinetic findings). Thereafter, selection and efficacy of cytotoxic chemotherapy and endocrine treatment is discussed and related to the prognostic different entities. The current therapeutic regimen of our group is outlined.

摘要

乳腺癌是女性癌症死亡的最常见原因。这种疾病的治愈概率低于50%。然而,对于某些疾病阶段,现代治疗策略的应用可以改善预后。本文首先探讨预后、分期与肿瘤细胞特征(受体状态和细胞动力学结果)之间的关系。此后,讨论了细胞毒性化疗和内分泌治疗的选择与疗效,并将其与不同的预后实体相关联。概述了我们团队目前的治疗方案。

相似文献

1
[Therapeutic strategies in the treatment of breast cancer (author's transl)].乳腺癌治疗中的治疗策略(作者译)
Wien Klin Wochenschr. 1981 Sep 18;93(17):531-41.
2
[Role of biological indicators in the therapeutic decision in breast carcinoma].
Chir Ital. 1995;47(4):15-22.
3
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.基于新辅助内分泌治疗后肿瘤特征的雌激素受体阳性乳腺癌预后预测
J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23.
4
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.前列腺特异性抗原(PSA)的表达与复发性乳腺癌对他莫昔芬治疗的不良反应相关。
Br J Cancer. 1999 Feb;79(5-6):888-94. doi: 10.1038/sj.bjc.6690142.
5
Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.利用雌激素受体信息在美国推广乳腺癌辅助多药化疗和他莫昔芬:1975 - 1999年
J Natl Cancer Inst Monogr. 2006(36):7-15. doi: 10.1093/jncimonographs/lgj003.
6
Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.bcl-2蛋白的表达可预测可手术的淋巴结阳性乳腺癌辅助治疗的疗效。
Clin Cancer Res. 1995 Feb;1(2):189-98.
7
[Clinical analysis of resectable breast cancer: a report of 6 263 cases].可切除乳腺癌的临床分析:6263例报告
Ai Zheng. 2005 Mar;24(3):327-31.
8
[The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].[类固醇受体对乳腺癌患者预后及激素治疗的重要性:荷兰东南部的一项回顾性研究]
Ned Tijdschr Geneeskd. 1998 Aug 1;142(31):1772-8.
9
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.新型芳香化酶抑制剂伏罗唑(R83842)用于他莫昔芬治疗后病情进展的绝经后晚期乳腺癌女性患者的II期研究。
Clin Cancer Res. 1995 Mar;1(3):287-94.
10
Prognostic factors affecting response to aminoglutethimide in advanced breast cancer.影响晚期乳腺癌对氨鲁米特反应的预后因素。
Anticancer Res. 1993 Jul-Aug;13(4):1235-7.